Ironwood Pharma (NASDAQ: IRWD) that the Phase III clinical trial of its 72 mcg dose of linaclotide in adults with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE